PRESS RELEASE published on 01/22/2025 at 07:00, 1 year 3 months ago Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma EU approves Sarclisa as first anti-CD38 therapy in combination with VRd for transplant-ineligible NDMM based on positive IMROZ study results. Third indication for Sarclisa in the EU Multiple Myeloma Sarclisa EU Approval VRd Anti-CD38 Therapy
BRIEF published on 01/15/2025 at 18:35, 1 year 3 months ago Sanofi : État des droits de vote et actions en novembre 2024 Droits De Vote Actions Informations Réglementées Sanofi Novembre 2024
BRIEF published on 01/15/2025 at 18:35, 1 year 3 months ago Sanofi: Status of voting rights and shares in November 2024 Voting Rights Actions Regulated Information Sanofi November 2024
PRESS RELEASE published on 01/15/2025 at 18:30, 1 year 3 months ago Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024 Annonce du nombre total de droits de vote et d'actions de Sanofi selon les réglementations en vigueur Autorité Des Marchés Financiers Droits De Vote Actions Investisseurs Sanofi
BRIEF published on 12/17/2024 at 13:35, 1 year 4 months ago Sanofi and Teva Announce Promising Phase 2b Results for Duvakitug Ulcerative Colitis Crohn’s Disease Duvakitug Phase 2b Results Sanofi And Teva Partnership
BRIEF published on 12/17/2024 at 13:35, 1 year 4 months ago Sanofi et Teva annoncent des résultats prometteurs de phase 2b pour Duvakitug Maladie De Crohn Rectocolite Hémorragique Duvakitug Résultats De La Phase 2b Partenariat Entre Sanofi Et Teva
PRESS RELEASE published on 12/17/2024 at 13:30, 1 year 4 months ago Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Sanofi and Teva announce positive phase 2b results for duvakitug in ulcerative colitis and Crohn's disease, showing promising potential in IBD. Phase 3 development planned Ulcerative Colitis Sanofi Teva Crohn's Disease Duvakitug
PRESS RELEASE published on 12/17/2024 at 13:30, 1 year 4 months ago Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn Les résultats positifs de phase IIb du duvakitug pour la colite ulcéreuse et la maladie de Crohn ouvrent la voie à un programme de développement de phase III par Sanofi et Teva Maladie De Crohn Colite Ulcéreuse Duvakitug Phase IIb Sanofi Teva
BRIEF published on 12/17/2024 at 07:35, 1 year 4 months ago Sanofi Releases Q4 2024 Aide-mémoire for Financial Modelling Financial Results Investors Sanofi Aide-mémoire Q4 2024
BRIEF published on 12/17/2024 at 07:35, 1 year 4 months ago Sanofi publie son aide-mémoire pour le quatrième trimestre 2024 sur la modélisation financière Résultats Financiers Investisseurs Sanofi Aide-mémoire 4e Trimestre 2024
Published on 05/07/2026 at 14:00, 25 minutes ago Adcore to Publish First Quarter 2026 Results on May 14, 2026
Published on 05/07/2026 at 14:00, 25 minutes ago Metallic Minerals Announces Option Agreement with Argyle Resources on McKay Hill Property, Yukon
Published on 05/07/2026 at 13:30, 55 minutes ago UniDoc to Update and Relaunch Legacy eHealth Systems with Pawnee Mental Health Services Across Rural Kansas
Published on 05/07/2026 at 13:00, 1 hour 25 minutes ago Eagle Plains Expands George Lake Deposit Mineralization, Reports 3.48% Zn+Pb over 45.1m in Step-out Drilling
Published on 05/07/2026 at 14:05, 20 minutes ago Addepar Introduces ADX, Enabling Data Activation and AI at Scale
Published on 05/07/2026 at 14:02, 22 minutes ago Genel Energy PLC: Results of Annual General Meeting 7 May 2026
Published on 05/07/2026 at 13:50, 35 minutes ago Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure
Published on 05/07/2026 at 07:43, 6 hours 42 minutes ago ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 20 hours 25 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 20 hours 25 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 20 hours 25 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026